LI SUN^1,#, SHICHAO ZHUO^2,#, XIAOXIN LI², HUSHENG KONG³, WEIWEI DU³, CHONG ZHOU⁴, JUNXING HUANG^1,*

Oncology Research, Vol.33, No.3, pp. 641-651, 2025, DOI:10.32604/or.2024.050057 - 28 February 2025

Abstract Background: Cisplatin (DDP) has been used in the treatment of various human cancers. However, DDP alone lacks efficacy in treating triple-negative breast cancer (TNBC), and its clinical application is often hampered by side effects. Astragalus polysaccharide (APS) is one of the active components extracted from Astragalus membranaceus and has gained attention for its various biological properties. This research is aimed to evaluate the effectiveness of a combination of APS and DDP on TNBC and explore the potential mechanisms. Methods: The efficacy and mechanisms of single or combined treatment were evaluated using Cell Counting Kit-8 (CCK8) assay, Annexin… More >

HUAN GAO^1,2, JIE ZHANG¹, TONY G. KLEIJN^1,3,4, ZHAOYONG WU⁵, BING LIU^1,6, YUJIN MA⁶, BAOYUE DING^1,*, DONGFENG YIN^2,*

Oncology Research, Vol.32, No.4, pp. 769-784, 2024, DOI:10.32604/or.2023.044276 - 20 March 2024

Abstract Bone metastasis secondary to breast cancer negatively impacts patient quality of life and survival. The treatment of bone metastases is challenging since many anticancer drugs are not effectively delivered to the bone to exert a therapeutic effect. To improve the treatment efficacy, we developed Pluronic P123 (P123)-based polymeric micelles dually decorated with alendronate (ALN) and cancer-specific phage protein DMPGTVLP (DP-8) for targeted drug delivery to breast cancer bone metastases. Doxorubicin (DOX) was selected as the anticancer drug and was encapsulated into the hydrophobic core of the micelles with a high drug loading capacity (3.44%). The… More > Graphic Abstract